| Literature DB >> 25434001 |
Yeon Sun Lee1, Sara M Hall2, Cyf Ramos-Colon2, Michael Remesic2, Lindsay LeBaron2, Ann Nguyen2, David Rankin3, Frank Porreca3, Josephine Lai3, Victor J Hruby4.
Abstract
It has been shown that under chronic pain or nerve injury conditions, up-regulated dynorphin A (Dyn A) interacts with bradykinin receptors (BRs) to cause hyperalgesia in the spinal cord. Thus BRs antagonist can modulate hyperalgesia by blocking Dyn A's interaction with the BRs in the central nervous system. In our earlier structure-activity relationship (SAR) study, [des-Arg(7)]-Dyn A-(4-11) 13 was discovered as a minimum pharmacophore for rat brain BRs with its antagonist activity (anti-hyperalgesic effect) in in vivo tests using naïve or injured animals. We have pursued further modification on the [des-Arg(7)]-Dyn A analogues and identified a key insight into the pharmacophore of the rat brain BRs: amphipathicity.Entities:
Keywords: Amphipathicity; Anti-hyperalgesic effect; Bradykinin receptors; Dynorphin A; Non-opioid
Mesh:
Substances:
Year: 2014 PMID: 25434001 PMCID: PMC4258438 DOI: 10.1016/j.bmcl.2014.11.026
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823